AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Many healthcare companies’ shares ended in the green territory today.
- The S&P/ASX 200 Healthcare Index also closed 1.20% higher today at 41,331.20.
- During the COVID-19 epidemic, certain companies have seen higher sales of pharmaceuticals and equipment, which has piqued investors' interest.
The healthcare sector is Australia's largest employer, employing over 14.2% of the population. It includes a large commercial insurance industry as well as Medicare, Australia's national healthcare programme.
During the COVID-19 epidemic, certain companies have seen an increased sale of pharmaceuticals and equipment, which has piqued investors' interest.
Today, many healthcare companies' shares ended in the green. This might be because of the S&P/ASX 200 Health Care [XHJ] Index which closed 1.20% higher at 41,331.20. Besides, all 11 sectors closed strong today, and healthcare was one of the top performers.
On this note, we will discuss three healthcare stocks that are into pharma, healthcare equipment, and services.
Also Read: From VIP to REG: Five ASX healthcare stocks with the highest dividend yield
Image Source: © 2022 Kalkine Media ®
Cochlear Limited (ASX:COH)
Cochlear Limited is an Australian firm that specialises in implantable hearing aids. The business creates and sells products and accessories for both adults and children. Cochlear implants, services, and acoustics are the company's three segments.
Most recently (on 27 April 2022), the company announced that it has agreed to buy Oticon Medical for DKK850 million (around AU$170 million) following Demant’s decision to exit its hearing implants business activities.
Cochlear has agreed to provide continuous support for Oticon Medical's network of more than 75,000 hearing implant patients, which includes both cochlear and acoustic implants, as part of the deal.
On Friday (29 April 2022), Cochlear's shares closed trading at AU$230.87 each, up 0.61% on ASX today. The company has provided around 7% YTD returns, mainly because of the strong half-yearly results shares in February.
Healius Limited (ASX:HLS)
For more than three decades, Healius has been one of Australia's leading healthcare companies. It offers all Australians with high-quality, cheap, and accessible healthcare.
Last month, the company announced to sell Adora Fertility and three co-located Healius Day Hospitals (collectively Adora) to funds managed by Liverpool Partners. The deal would be valued at AU$30.5 million in cash and debt-free terms.
Also Read: Healius (ASX:HLS) inks deal to sell Adora Fertility, shares fall
Healius is currently divided into three divisions: pathology, imaging, and day hospitals. the company provides specialty diagnostic services to consumers and their referring practitioners and allows independent healthcare professionals to provide care in its day hospitals.
Shares of Healius ended 1.35% higher today (29 April 2022) at AU$4.52 each share. The company has recorded negative growth of around 14% YTD.
Source: © Bogdanhoda | Megapixl.com
CSL Limited (ASX:CSL)
CSL Limited is an ASX-listed healthcare large-cap stock that engages in pharmaceutical and diagnostic research, development, manufacturing, and marketing. Besides Australia, the corporation maintains offices in Switzerland, the United Kingdom, and the United States.
Last week (on 21 April 2022), CSL announced that it issued bonds worth US$4 billion in the US market. These bonds have been issued by CSL Finance and are guaranteed by CSL.
CSL shares last exchanged hands at AU$273.30 each, up 1.66% on ASX today (29 April 2022), and have fallen around 6% YTD.
Also Read: CSL Limited (ASX:CSL) shares edge higher after US$4B fund raise
